Please login to the form below

Not currently logged in


This page shows the latest LentiGlobin news and features for those working in and with pharma, biotech and healthcare.

bluebird bio says AML case "very unlikely" to be related to gene therapy LentiGlobin

bluebird bio says AML case

bluebird bio's gene therapy LentiGlobin is used to treat sickle cell disease. ... Phase 3 trials of LentiGlobin have been placed on temporary hold following the SUSAR reports. .

Latest news

More from news
Approximately 5 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    LentiGlobin (betibeglogene darolentivec), an Orphan Drug and Breakthrough Therapy from Bluebird Bio, corrects the defect causing beta thalassemia, a blood disorder that causes life-threatening anaemia. ... The initial studies for LentiGlobin in

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    7. LentiGlobin TDT – a gene therapy first for Europe. Gene therapy company Bluebird Bio is on course to gain approval for its first product this year – and Europe is expected to ... The Cambridge, Massachusetts-based firm filed its gene therapy

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    The Cambridge, Mass-based company is set to file the first of its four candidates, LentiGlobin TDT, a gene therapy for patients with the rare blood disorder beta thalassemia, by the ... Pharmaceutical Market Europe spoke to Bluebird’s CEO Nick Leschly

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...